Clinical and biomarker results from E7386 study 102: Global dose-expansion cohort of E7386+lenvatinib (LEN) in patients (pts) with advanced/recurrent endometrial cancer (aEC) that progressed on platinum-based chemotherapy (PBC) and an anti-PD-(L)1 immunotherapy (IO)
  • Lee, J-Y.
  • Hasegawa, K.
  • Kim, B-G.
  • Berman, B.
  • Suzuki, S.
  • 외 12명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Clinical and biomarker results from E7386 study 102: Global dose-expansion cohort of E7386+lenvatinib (LEN) in patients (pts) with advanced/recurrent endometrial cancer (aEC) that progressed on platinum-based chemotherapy (PBC) and an anti-PD-(L)1 immunotherapy (IO)
저자
Lee, J-Y.Hasegawa, K.Kim, B-G.Berman, B.Suzuki, S.Corr, B. R.Yunokawa, M.Orr, D.Yamamoto, N.Soliman, P.Miller, D. S.Potdar, A.Shen, J.Dutta, L.Wu, J.McKenzie, J.Makker, V.
DOI
10.1016/j.annonc.2025.08.1789
발행일
2025-09
유형
Meeting Abstract
저널명
Annals of Oncology
36